B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

PURPOSE: The advent of immune checkpoint inhibitors (ICIs) is a revolutionary breakthrough. However, without the selection of a specific target population, the response rate of ICI therapy in lung adenocarcinoma (LUAD) is low, so a clinical challenge has arisen in effectively using biomarkers to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Anqi, Fang, Jianbo, Cheng, Quan, Liu, Zaoqu, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514294/
https://www.ncbi.nlm.nih.gov/pubmed/36176353
http://dx.doi.org/10.2147/JIR.S379016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514294/
https://www.ncbi.nlm.nih.gov/pubmed/36176353
http://dx.doi.org/10.2147/JIR.S379016

Ejemplares similares